Patent ID: 11965156
Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
Field: Biotechnology (Chemistry)
Classification: CPC C | IPC C

Claim 0:
1. A method for amplifying nucleic acids from a urine sample for detection of RNA expression associated with a cancer, comprising;
a) separating urine sediment from the soluble urine fraction of a urine sample obtained from an individual suspected of having cancer, wherein RNA associated with the cancer is present in the soluble urine fraction,
b) concentrating the soluble urine fraction by ultrafiltration using a filter having a nominal molecular weight limit of between about 3,000 daltons and about 100,000 daltons, to produce a soluble urine concentrate, wherein the volume of the soluble urine concentrate is reduced at least 50% from the original urine volume,
c) isolating RNA from the soluble urine concentrate produced in step b),
d) reverse transcribing the RNA from the soluble urine concentrate produced in step c) to form cDNA; and
e) amplifying the cDNA produced in step d), wherein the cancer-associated RNA is selected from the group consisting of prostate cancer antigen 3 (PCA3), p antigen family, member 4 (PAGE4), solute carrier family 45, member 3 (SLC45A3), kallikrein-related peptidase, member 3 (KLK3), phosphoinositide-3-kinase, alpha polypeptide (PIK3CA), erythroblastic leukemia viral oncogene homolog 2 (ERBB2), hyaluronoglucosaminidase (HYAL1), bladder cancer associated protein (BLCAP), solute carrier family 35, member E3 (SLC35E3), tumor protein p53 (TP53), and suppressor of tumorigenicity 20 (ST20).